Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation
This article was originally published in The Tan Sheet
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
You may also be interested in...
Rx-to-OTC switch sponsors should not wait for FDA to act on NSURE before proposing innovative switch solutions, because reviewers are open to discussing ideas now, an agency official says. Some experts predict the new switch paradigm will not yield concrete regulatory changes, and are promoting other ways to expand OTC access.
FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.